Health Condition 1: N040- Nephrotic syndrome with minor glomerular abnormality Health Condition 2: N041- Nephrotic syndrome with focal andsegmental glomerular lesions Health Condition 3: N048- Nephrotic syndrome with other morphologic changes Health Condition 4: N049- Nephrotic syndrome with unspecified morphologic changes Health Condition 5: N045- Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis Health Condition 6: N042- Nephrotic syndrome with diffuse membranous glomerulone
Conditions
Interventions
Intervention1: Tolvaptan: Oral tolvaptan as single daily dose based on following weight for 48 hours
- more than 15 kg body weight - 7.5 mg/day
- 15-29.9 kg body weight - 15 mg/day
- 30 kg body weig
Sponsors
Department of Pediatrics
Eligibility
Inclusion criteria
Inclusion criteria: 1) Nephrotic syndrome aged between 5 and 14 years with moderate to severe edema 2) Patients not responding to oral furosemide for up to 24 hours (decrease in 3% body weight or urine output 3) Parents willing to give informed written consent
Exclusion criteria
Exclusion criteria: 1) Patients with hypovolemia 2) Patients with cerebral venous sinus thrombosis 3) Serum sodium 140 meq/L 4) eGFR 5) SGOT/SGPT > 2 ULN
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| • Percentage of weight loss over 48 hours • Serum sodium every 12 hourly for 48 hours • Urine and serum osmolality every 24 hours for 48 hours • Urine sodium/ potassium/ creatinine every 24 hours for 48 hours • Adverse effects Timepoint: 0 Hours 12 hours 24 hours 36 hours 48 hours | — |
Primary
| Measure | Time frame |
|---|---|
| Urine output over the first 48 hours (ml/kg/hr)Timepoint: 0 hours 12 hours 24 hours 36 hours 48 hours | — |
Countries
India
Contacts
Public ContactDr Aarchie Gupta
Postgraduate Institute of Medical Education and Research
Outcome results
None listed